稳心颗粒联合美托洛尔对冠心病心律失常的治疗意义探究

Therapeutic significance of Wenxin granules combined with metoprolol in treatment of coronary heart disease and arrhythmia

目的对稳心颗粒联合美托洛尔对冠心病心律失常的治疗意义进行探讨。方法选取2015年4月-2016年4月于我院心血管科收治的90例冠心病心律失常患者作为研究对象,采取双盲法将其随机分为对照1组、2组与观察组,对照1组给予稳心颗粒进行治疗,对照2组给予美托洛尔进行治疗,观察组给予稳心颗粒联合美托洛尔进行治疗,比较3组临床疗效。结果观察组治疗显效率56.67%、无效率6.67%、总有效率93.33%相较于对照1组,对照2组差异显著,P<0.05;治疗后,观察组PR期间(0.138±0.018)s、QRS波时限(0.081±0.005)s、QTc间期(0.48±0.05)s相较于对照1组、2组差异显著,P<0.05;观察组不良反应发生率10%相较于对照1组13.33%、对照2组20%差异显著,P<0.05。结论稳心颗粒联合美托洛尔治疗冠心病心律失常疗效较好,值得临床推广使用。

Objective To investigate the therapeutic significance of Wenxin granules combined with metoprolol in the treatment of coronary heart disease and arrhythmia. Methods A total of 90 patients with coronary heart disease and arrhythmia who were admitted to Department of Cardiology in our hospital from April 2015 to April 2016 were enrolled as study subjects and randomly divided into control groups 1 and 2 and observation group using the double-blind method. The patients in control group 1 were given Wenxin granules, those in control group 2 were given metoprolol, and those in the observation group were given Wenxin granules combined with metoprolol. The clinical outcome was compared between the three groups. Results The observation group had a marked response rate of56.67%, a non-response rate of 6.67%, and an overall response rate of 93.33%, and these rates showed significant differences between the observation group and control groups 1 and 2（P〈0.05）. After treatment, the observation group had a PR interval of 0.138 ±0.018 s, a QRS duration of 0.081 ±0.005 s, and a QTc interval of 0.48 ±0.05 s, and these parameters showed significant differences between the observation group and control groups 1 and 2（P〈0.05）. The incidence of adverse events showed significant differences between the observation group and control groups 1 and 2（10% vs 13.33% /20%, P〈0.05）. Conclusion Wenxin granules combined with metoprolol has a good effect in the treatment of coronary heart disease and arrhythmia and hold promise for clinical application.